Use of GLP-1 peptides

• US 20030232754A1
• Filed: 03/06/2003
• Published: 12/18/2003
• Est. Priority Date: 11/12/1996
• Status: Abandoned Application

• Current Assignee: Arne Vernon Astrup, Birgitte Schjellerup Wulff, Jens Juul Holst, Lars Thim, Liselotte Bjerre Knudsen, Martin Edward Judge
• Original Assignee: Arne Vernon Astrup, Birgitte Schjellerup Wulff, Jens Juul Holst, Lars Thim, Liselotte Bjerre Knudsen, Martin Edward Judge
• Inventors: Astrup, Arne Vernon, Thim, Lars, Holst, Jens Juul, Wulff, Birgitte Schjellerup, Knudsen, Liselotte Bjerre, Judge, Martin Edward
• Application Number:
  US10/382,438
• Publication Number:
  US 20030232754A1
• Time in Patent Office: Days
• US Class Current: 514/4.9
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents

Abstract

GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.

Claims

1. Use of GLP-1(1-45) or a fragment or an analogue thereof for the preparation of a medicament for peripheral administration for use in the suppression of appetite or induction of satiety.

2. Use according to claim 1 of GLP-1(1-39) or an analogue thereof.

3. Use according to claim 1 of GLP-1(1-38) or an analogue thereof.

4. Use according to claim 1 of GLP-1(1-37) or an analogue thereof.

5. Use according to claim 1 of GLP-1(1-36) or an analogue thereof.

6. Use according to claim 1 of GLP-1(1-35) or an analogue thereof.

7. Use according to claim 1 of GLP-1(1-34) or an analogue thereof.

8. Use according to claim 1 of GLP-1(7-45) or an analogue thereof.

9. Use according to claim 1 of GLP-1(7-39) or an analogue thereof.

10. Use according to claim 1 of GLP-1(7-38) or an analogue thereof.

11. Use according to claim 1 of GLP-1(7-37) or an analogue thereof.

12. Use according to claim 1 of GLP-1(7-36) or an analogue thereof.

13. Use according to claim 1 of GLP-1(7-35) or an analogue thereof.

14. Use according to claim 1 of GLP-1(7-34) or an analogue thereof.

15. Use of the C-terminal amide of any of the compounds mentioned in any one of claims 1-14 for the preparation of a medicament for peripheral administration for use in the suppression of appetite or induction of satiety.

16. A pharmaceutical composition for peripheral administration comprising a compound as mentioned in any one of the claims 1-15 for the prophylaxis or treatment of diseases or disorders associated with impaired appetite regulation.

17. A pharmaceutical composition for peripheral administration comprising a compound as mentioned in any one of the claims 1-15 for the prophylaxis or treatment of obesity.

18. A method of treating or preventing diseases or disorders associated with impaired appetite regulation or feeling of satiety, the method comprising administering to an individual in need of such treatment an amount of a compound according to any one of the claims 1-15 sufficient to suppress appetite or induce satiety in said individual.

19. A method of treating or preventing obesity the method comprising administering to an individual in need of such treatment a sufficient amount of a compound according to any one of the claims 1-15.